NKCL Bio Group will participate as the primary sponsor of the GCC Medical Forum 2023 event.
The forum, hosted by Saudi Aramco and the Saudi Ministry of Health and Welfare and supervised by the Royal Family Office, will be held at the Mansad Riyadh Radisson Collection Hotel in the capital of Saudi Arabia at the end of April, after Ramadan.
NKCL Bio Group is a company that leads the next-generation anti-cancer market through immuno-anticancer drugs using NK cells and leads anti-aging products and services based on its technology. The company leads the “personalized immune care” market by expanding its business areas in various ways through the expansion of research institutes for NK cell R&D, the establishment of GMP automatic culture centers, and the commercialization of microbiome foods.
Many local participants, including the Saudi royal family, high-ranking government officials related to cancer, and officials from government hospitals, will attend this forum.
In particular, the main content of this forum includes medical surgical equipment company introduction and hospital introduction speech, opening hospitals in Saudi Arabia, medical equipment export individual consultation-investment matching, Korean cancer-related hospital and university hospital Saudi branch establishment speech, opening anti-aging hospitals, and attracting royal family patients.
According to the forum, about 20 companies have expressed their intention to participate in the forum, and an additional 30 companies are being invited. The medical fields Saudi Arabia prefers include plastic surgery, male plastic surgery, reconstructive surgery (wound reconstruction, nose, ear, etc.), hospitals specializing in obesity, NK cell and stem cell companies, cancer-related companies, anti-aging companies, cosmetics, and medical blockchain startups.
